| Title: | Assessing Europe’s policy readiness to confront the MASLD/MASH public health threat : Chronic liver disease in Europe |
|---|
| Authors: | ID Lazarus, Jeffrey Victor (Author)
ID White, Trenton M. (Author)
ID Agirre-Garrido, Leire (Author)
ID Abeysekera, Kushala W. M. (Author)
ID Brennan, Paul N. (Author)
ID Brůha, Radan (Author)
ID Buttigieg, Stefan (Author)
ID Carrieri, Patrizia (Author)
ID Cortez-Pinto, Helena (Author)
ID Jensterle Sever, Mojca (Author), et al. |
|---|
| Files: |  PDF - Presentation file, download (6,36 MB)
MD5: E62A9685326D81A930454BE19D19733E
 URL - Source URL, visit https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00125-0/fulltext
|
|---|
| Language: | English |
|---|
| Typology: | 1.02 - Review Article |
|---|
| Organization: |  UKC LJ - Ljubljana University Medical Centre
|
|---|
| Abstract: | Metabolic dysfunction-associated steatotic liver disease (MASLD) is a public health threat in Europe. With an estimated 30.4% prevalence among the adult population in the European Union and United Kingdom, it is the most common chronic liver disease and is closely linked to obesity and type 2 diabetes, which can be considered as in- dicator conditions. Despite the scale of the burden, the spectrum of MASLD, including its advanced form, metabolic dysfunction-associated steatohepatitis (MASH), is weakly represented—or even absent—from health policy and development agendas. Further, the extent to which regional and national clinical practice guidelines (CPGs) on other liver diseases and related fields incorporate information on MASLD/MASH prevention or management is unclear. In this Series paper, we reviewed policy attention to MASLD/MASH across the European Union and the United Kingdom. We report low policy readiness across European countries to address MASLD/MASH. Only two (7.1%), Romania and Sweden, had a subnational strategy, while 13 (46.4%) referenced MASLD/MASH in other national or subnational action plans, predominantly those for liver disease and obesity. No country included MASLD/MASH in its priority non-communicable disease list. Additionally, 15 (53.6%) countries had national MASLD/MASH CPGs, while 25 (89.3%) mentioned MASLD/MASH in other national CPGs, most often those for obesity, diabetes, cirrhosis, liver transplantation, and primary care, respectively. We conclude that MASLD/MASH remains insuffi- ciently addressed from a policy perspective, which contributes to low readiness to address this public health threat. |
|---|
| Keywords: | health systems, non-communicable diseases, food policy, liver health |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Year of publishing: | 2026 |
|---|
| Number of pages: | str. 1-17 |
|---|
| Numbering: | Vol. 65, article no. ǂ101713 |
|---|
| PID: | 20.500.12556/DiRROS-31246  |
|---|
| UDC: | 614 |
|---|
| ISSN on article: | 2666-7762 |
|---|
| DOI: | 10.1016/j.lanepe.2026.101713 |
|---|
| COBISS.SI-ID: | 280703747 |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 6. 6. 2026;
|
|---|
| Publication date in DiRROS: | 23.07.2026 |
|---|
| Views: | 111 |
|---|
| Downloads: | 110 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
